Anixa Biosciences Inc (ANIX) officer granted 175,000 stock options at $3.18

Rhea-AI Filing Summary

Anixa Biosciences Inc executive Michael J. Catelani, who serves as President, COO and CFO, reported a new stock option grant. On January 5, 2026, he received an employee stock option giving him the right to buy 175,000 shares of Anixa common stock at an exercise price of $3.18 per share under the company’s 2018 Share Incentive Plan. The filing states that these options were granted at no cost to him as a derivative security and are held directly.

The options vest in thirty-six equal monthly installments beginning on January 31, 2026, meaning portions of the grant become exercisable each month over a three-year period. After this grant, Catelani beneficially owns 175,000 stock options, all reported as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Catelani Michael

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, COO & CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option(1)	$3.18	01/05/2026		A		175,000		(2)	01/05/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

2. The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.

	/s/ Michael J. Catelani	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Anixa Biosciences Inc (ANIX) report in this Form 4?

The Form 4 reports that Michael J. Catelani, Anixa Biosciences Inc’s President, COO and CFO, received an employee stock option grant for 175,000 shares of common stock.

How many Anixa Biosciences Inc (ANIX) options were granted to Michael J. Catelani and at what price?

Catelani was granted an employee stock option covering 175,000 shares of Anixa Biosciences Inc common stock with an exercise price of $3.18 per share.

When do Michael J. Catelani’s Anixa (ANIX) stock options vest and become exercisable?

The filing explains that the options vest and become exercisable in thirty-six (36) equal monthly installments, beginning on January 31, 2026.

Under which equity plan were the Anixa Biosciences Inc (ANIX) options granted to Michael J. Catelani?

The options were granted as a Right-To-Buy under the Anixa Biosciences, Inc. 2018 Share Incentive Plan, as stated in the footnotes.

Does Michael J. Catelani hold the reported Anixa (ANIX) options directly or indirectly?

The Form 4 shows that Catelani’s 175,000 stock options are held with direct (D) ownership, with no indirect ownership entity listed.

What is the total number of Anixa Biosciences Inc (ANIX) derivative securities Michael J. Catelani owns after this grant?

Following the reported transaction, Catelani beneficially owns 175,000 derivative securities in the form of stock options on Anixa Biosciences Inc common stock.